The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target of $18 for Apollomics is a positive signal for the stock. This recommendation suggests that the analyst believes the stock has potential for growth and is undervalued. As a result, this news is likely to have a positive short-term impact on the stock price.